DrugPamphlet Egypt: Egyptian Drug Guide & Commentaries

Pariet DT CaSa an rooc stmuatec ac s&Dretlon i nors arer tne trst case ot  raoeprazole scwim are 69% and 82% respectively and the duration of inhibition lasts up to 48 hours. The inhibitory effect of rabeprazole sodium on acid secretion Increases slightly with repeated once-daily dosing, achieving steady state inhibition after three days. When the drug is discontinued, secretory activity normalises over 2 to 3 days. Helicobacter pylon is associated with acid peptic disease including duoderial ulcer (DU) and gastric ulcer (GU). H. pylon is implicated as a major contributing factor in the development of gasmtis and ulcers in such patients. Recent evidence also suggests a causative link between H. pylon and gastric carcinoma. Rabeprazoe has been shown to nave a bactericidal effect on H. pylon in vitro. Eradication of H. pylon with Pariet (rabeprazole) and antimicrobials is associated with high rates of healing of mucosal lesions. Clinical experience from controlled rando...

Pariet J-2UU Overdose En un est Symptoms de edad Experience to date wfth deilberate or accidental overdose is limited. The maximum established reaciona exposure has not exceeded 60 mg twice daily, or 160 mg once daily. Effects are generally minimal, en el trat representative of the known adverse event profile, and reversible without further medical inteNention. cautelosc Treatment interacci No spectic antidote is known. Rabeprazole sodium is extensively protein bound and is, therefore, Como oc not readIy dialysable. As in any case of overdose, treatment should be symptomatic and general rabeprazc supportive measures should be utilised. P450 (C PHARMACOLOGICAL PROPERTIES menta mt Pharmacodynamic properties fenitomna, Mechanism ofAction El rabepr Rabeprazole sodium beiongs to the class of anti-secretory compounds, the substituted benzimida- Puede oc zoIS, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric vado una acid sec...

Pariet mqes agt,ês — par exempie un gor!flemeflt du visage, une hypotension et ire dyspnée — ont été rappo,lés chez des patients traités par Paet ; ces effets ont généralement dispfti après arrèt dii tratemenL Urie thrombocytopénie, urie neutropérie et une Ieucopénie ont êté rarement rapportées. II y a eu des rapports denzymes hépatiques aecrus et, rarement, des rapports d’hépatite et d’ictère. Ot note auss de rares rapports d’encéphalopathie hépatique chez des patients présentant une cirthose sous-jacente. II y a eu do trés rares mentions de néphrite interstitiefle, de gynecomasbe, d’érythème polymorphe, de necroyse épiderrnique toxique (NET) et de syndrome de StevensJohnson. Surdosage Symptômes L’expérience acquise a ce jour avec une surdose déhbérée ou accienteIe est limitee. Lexpostion maximale étabIe n’a pas dépassé 60 ng deux fois par jour, ou 160 mg une fos parjour. Les effets sont généraiernent mnimes, représentatifs dii prcfil d’effets secondaires indésirables du rn...

Parie t Le rabéprazole sodique est, comme tout autre mernbre de ra classe des inhbiteurs de Ia pompe a protons (IPP), métabolisé par le système hépatique du cytochrorne P450 (CYP45O), qui métabohse les mèdicaments. Des etudes chez des volontaires sains ont démontré que le rabéprazole sodique n’a pas d’interaction diniquement significative avec les mêdicaments étudiés, a savor Ia warfarine, Ia phénytomne, Ia théophylline ou te diazépani, qui sont métabolisés par le système CYP45O. Le rabéprazoe sodique inhibe puissamment et durablement Ia sécrétion acide gastrique. II peut donc se produire une interaction avec des composes dont Itabsorption est dèpendante du pH, et c’est pourquoi Ia potentialité d’une telle interaction a été étudiée. La co-administration du rabéprazde sodque se traduit par tine reduction de 33% des concentrat,ons de kétoconazoe et tine hausse de 22% des concentrations minimales de digoxine chez les sujets normaux, En conséqueiice, ii peut s1avérer nécessaire de s...

Thiote x Thiotex®                     Rest Of Pamphlet   Thioctic Acid (X—LIpoIc Acid - Composition - Thioctic Acid (OC-Lipoic acid ) 300 mg or 600 mg ( ThIote)orte). Pharmacokinetics OC-Lipoic acid (ALA) can be synthesized by both animals and humans. It seems to be readily absorbed from an oral dose and is converted easily to its reduced form, dihydrolipoic acid (DHLA), in many tissues of the body. An in vitro study indicated that normal mammalian cells appear to be capable of taking up OC-lipoic actd and reck1cng it to OH LA. The effects of both ALA and DHLA are present both intra- and extracellularly when exposed to extracellular lipoic acid, e.g. in an oral dose. Mechanisms of Action ThloteXis a potent antioxidant in both fat- and water-soluble mediums. Furthermore, its antioxidant activity extends to both the oxidized form and its reduced form. DHLA is capable of regenerating ascorbic a...

OXY-POL For the Medical Profession Only OXY-POL® Eye Ointment The Broad Spectrum Combination Composition: Each gm contains: Oxytetracycline hydrochloride 5 mg Polymyxin - B - sulphate 10,000 LU. Properties and Mode of Action: OXY-POL combines the action of two antibacterial agents. Oxytetracycline, is a broad spectrum bacteriostatic agent acting by inhibition of protein synthesis by binding tb the mRNA ribosome complex at the 30S subunit of susceptible organisms. It is active against Staphylococcus aureus, Streptococcus epidermidis, Neisseria gonorrhoeae, S.pneumoniae, H.influenzae, H.ducreyi, Kiebsiella pneumoniae, Yersinia pestis, E.coli, B.anthracis, Lymphogranuloma venerum and Chiamydia trachomatis. Polymyxin-B is a bactericidal antibiotic active against gram-negative bacteria including Pseudomonas aeruginosa. Indications: OXY-POL is indicated for the treatment of superficial ocular infections due to susceptible organisms such as blepharitis, conjunctivitis, b...